CDK2 and breast cancer: Alternatively, the expression of the estrogen receptor on palbociclib-resistant breast cancer cells has been described to sensitize them towards adenoviral replication and oncolysis due to their low antiviral IFN response and increased cyclin-dependent kinase-2 activation [72].